Omega Protein Corp

Omega Protein — Proxy Contest (June 2016)

48 slides from Omega Protein's proxy contest presentation, Jun 8, 2016

  1. Slide 1: Omega Protein: A Case of Poor Board Quality, Capital Misallocation and Anti-Shareholder Corporate Governance

    Slide 1: Omega Protein: A Case of Poor Board Quality, Capital Misallocation and Anti-Shareholder Corporate Governance

    Omega Protein: A Case of Poor Board Quality, Capital Misallocation and Anti - Shareholder Corporate Governance © 2016 Wynnefield Capital, Inc. All rights reserved.

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    2 Disclaimer This presentation (the “Presentation”) is for discussion and general informational purposes only. It does not have regard to the s pec ific investment objective, financial situation, suitability, or the particular need of any specific person who may receive this Presentation, and should

  3. Slide 3: Table of Contents

    Slide 3: Table of Contents

    3 Table of Contents » Executive Summary 4 » Board Quality is a Critical Issue 13 » Total Share Return Driven by Many Factors 20 » Capital Misallocation Due to Non - Core Human Nutrition Acquisitions 24 » Poor Corporate Governance 29 » Conclusion 37 » Appendix I: Unfriendly Bylaws 39 » Appendix II: W

  4. Slide 4: Executive Summary

    Slide 4: Executive Summary

    4 Executive Summary

  5. Slide 5: Wynnefield Asks For Your Support: Vote FOR Michael N. Christodolou

    Slide 5: Wynnefield Asks For Your Support: Vote FOR Michael N. Christodolou

    5 Wynnefield Asks For Your Support VOTE FOR Independent Board Nominee Michael N. Christodolou » FOR electing directors with superior experience and expertise » FOR improving capital allocation policy » FOR addressing corporate governance » Wynnefield’s other nominee, David H. Clarke, subsequently ha

  6. Slide 6: Nominee comparison: Vote FOR the veteran, Michael Christodolou

    Slide 6: Nominee comparison: Vote FOR the veteran, Michael Christodolou

    6 Board Quality is a Critical Issue Nominee comparison A complicated company is not the place to learn Board skills: Vote FOR the veteran, Michael Christodolou Mr. Christodolou Mr. Ermers Public board years (excluding Omega Protein) 22 years None (1) Public company Chairman of the Board 12 years Non

  7. Slide 7: Wynnefield Capital Overview

    Slide 7: Wynnefield Capital Overview

    7 » Wynnefield employs an equity small - cap value special situations strategy with identifiable catalysts. » The investment team seeks out under - followed, misunderstood and undervalued companies which lead to the largest pricing ineffici encies and opportunities in the public market space. » The

  8. Slide 8: Wynnefield Capital history of introducing qualified Board nominees

    Slide 8: Wynnefield Capital history of introducing qualified Board nominees

    8 Wynnefield Capital has a history of introducing highly qualified Board nominees for its portfolio company boards » Wynnefield has successfully placed 11 i ndependent directors over the last 10 years. » Independent d irectors are not representatives of Wynnefield. They have no affiliation with and

  9. Slide 9: Unfriendly Shareholder Treatment

    Slide 9: Unfriendly Shareholder Treatment

    9 Unfriendly Shareholder Treatment Board rejects Wynnefield for a year . » May 2015: Oceana announces proposed acquisition of Daybrook for $382 million . At the time of Oceana’s announcement, Daybrook’s EV/EBITDA multiple was 7.96x ; OME shares traded at an EV/adjusted EBITDA multiple of 4.52x . » S

  10. Slide 10: Engagement Timeline Between Wynnefield and Omega Protein

    Slide 10: Engagement Timeline Between Wynnefield and Omega Protein

    10 Engagement Timeline Between Wynnefield and Omega Protein » June to July 2015 : Wynnefield’s initiated conversations with the Company. » August 4, 2015 and November 5, 2015 : The Company’s Board twice unilaterally and without shareholder approval adopted bylaw amendments. These amendments were des

  11. Slide 11: Omega Protein Overview

    Slide 11: Omega Protein Overview

    11 Omega Protein Overview Company Overview » Omega Protein was founded in 1913. » The Company’s shares trade under the ticker symbol “OME” and have traded on the NYSE for 18 years. » Export countries : 40+. » Products produced : 300+. » Manufacturing facilities : 8. » Fishing vessels : 30+. » Worldw

  12. Slide 12: Omega Protein Overview: Select Financials

    Slide 12: Omega Protein Overview: Select Financials

    12 Omega Protein Overview Select Financials Wynnefield’s view : Omega Protein’s core Animal Nutrition segment has generated consistent cash flow. The Human Nutrition segment primarily grew through incremental and larger acquisitions; this segment suffered significant operating losses, including mate

  13. Slide 13: Board Quality is a Critical Issue

    Slide 13: Board Quality is a Critical Issue

    13 Board Quality is a Critical Issue

  14. Slide 14: Wynnefield has No Confidence in Existing Board Members

    Slide 14: Wynnefield has No Confidence in Existing Board Members

    14 Board Quality is a Critical Issue Wynnefield has No Confidence in Existing Board Members Omega Protein’s current Board members have limited industry, public company, risk management, financial, operational, investm ent and public company experience. » Wynnefield believes existing Board members la

  15. Slide 15: Entrenched Directors Resulted in Bad Decisions

    Slide 15: Entrenched Directors Resulted in Bad Decisions

    15 Board Quality is a Critical Issue Entrenched Directors Resulted in Bad Decisions Omega Protein’s Current Board of Directors lack important experience and skills. OME Board OME Board Public Board years Human Nutrition acquisition Anti - Shareholder B ylaw of directors start date (excluding OME) re

  16. Slide 16: Nominee Comparison: Endorse the veteran, Michael Christodolou

    Slide 16: Nominee Comparison: Endorse the veteran, Michael Christodolou

    16 Board Quality is a Critical Issue Nominee Comparison A complicated public company is not the place to learn Board skills: Endorse the veteran, Michael Christodolou Mr. Christodolou Mr. Ermers Public board years (excluding Omega Protein) 22 years None (1) Public company Chairman of the Board 12 ye

  17. Slide 17: Wynnefield board nominees have relevant experience and are independent

    Slide 17: Wynnefield board nominees have relevant experience and are independent

    17 Board Quality is a Critical Issue Wynnefield board nominees have relevant experience and are independent to serve all shareholders Highly skilled nominee duo have complementary expertise and fill crucial voids on Omega Protein’s Board Michael N. Christodolou » Thirty years of investment and corpo

  18. Slide 18: Wynnefield Offers Superior Board Nominee: Michael N. Christodolou

    Slide 18: Wynnefield Offers Superior Board Nominee: Michael N. Christodolou

    18 Board Quality is a Critical Issue Wynnefield Offers Superior Board Nominee for Shareholder C onsideration Not one of Omega Protein’s existing Board members’ experience compares to Michael Christodolou’s - especially not Omega Protein’s Mr. Ermers. Michael N. Christodolou Omega Protein would benef

  19. Slide 19: Omega Protein Offers Superior Board Nominee: David H. Clarke

    Slide 19: Omega Protein Offers Superior Board Nominee: David H. Clarke

    19 Board Quality is a Critical Issue Omega Protein Offers Superior Board Nominee for Shareholder Consideration David H. Clarke Mr. Clarke’s industry knowledge and experience is so extensive, Omega Protein nominated him as a director on their slate. » Extensive industry knowledge : Mr. Clarke has hig

  20. Slide 20: Total Share Return Driven by Many Factors

    Slide 20: Total Share Return Driven by Many Factors

    20 Total Share Return Driven by Many Factors

  21. Slide 21: Total Share Return Driven By Many Factors

    Slide 21: Total Share Return Driven By Many Factors

    21 Total Share Return Driven By Many Factors OME: 1 - year return of 46.1% OME: 3 - year return of 80.8% OME: 5 - year return of 54.2% OME Proxy OME 10K OME Peer Group Peer Group » 1 - year: +46.1% +14.9% +16.4% » 3 - year: +80.8% +77.6% +74.5% » 5 - year: +54.2% +137.0% +119.1% (1) At the time of O

  22. Slide 22: Total Share Return Details

    Slide 22: Total Share Return Details

    22 Total Share Return Details Share appreciation driven by Animal Nutrition results and Non - Fundamental factors; Human Nutrition is a financial drag » May 19, 2015: Oceana Group Limited announces proposed acquisition of Daybrook Fisheries for $382 million . » Fact : Oceana disclosed Daybrook’s rev

  23. Slide 23: Total Share Return Details

    Slide 23: Total Share Return Details

    23 Total Share Return Details Share appreciation driven by Animal Nutrition results and Non - Fundamental factors; Human Nutrition represents a drag » November 4, 2015: Omega Protein releases Third Quarter financial results . » Fact : Reported 3Q15 revenue of $112.2mm and adjusted EBITDA of $28.7mm

  24. Slide 24: Capital Misallocation Due to Non-Core Human Nutrition Acquisitions

    Slide 24: Capital Misallocation Due to Non-Core Human Nutrition Acquisitions

    24 Capital Misallocation Due to Non - Core Human Nutrition Acquisitions

  25. Slide 25: Capital Misallocation Into Non-Core Human Nutrition Segment

    Slide 25: Capital Misallocation Into Non-Core Human Nutrition Segment

    25 Capital Misallocation Into Non - Core Human Nutrition Segment Abject Failure over Four Years Omega Protein’s total capital allocation into Human Nutrition Human Nutrition acquisitions (2) Acquisition Date Price Description Cyvex (3) December 2010 $13.2mm Ingredient supplier to nutraceutical indus

  26. Slide 26: Abject Failure over Four Years

    Slide 26: Abject Failure over Four Years

    26 Capital Misallocation into Non - Core Human Nutrition Segment Abject Failure over Four Years The Board and Management never delivered on Human Nutrition promises: » To reduce Animal Nutrition’s volatility through diversification. » To create an accretive operation through its Human Nutrition acqu

  27. Slide 27: Bret Scholtes and Pivotal's analyst agree on value loss

    Slide 27: Bret Scholtes and Pivotal's analyst agree on value loss

    27 Capital Misallocation into Non - Core Human Nutrition Segment Abject Failure over Four Years Bret Scholtes and Pivotal’s sell - side analyst – AGREE … » That Omega Protein’s Human Nutrition segment is worth $60 million less than its original capital allocation of approximately $ 160 million – nea

  28. Slide 28: Disappointing conclusion to strategic alternatives review

    Slide 28: Disappointing conclusion to strategic alternatives review

    28 Capital Misallocation into Non - Core Human Nutrition Segment Consistent Abject Failure Over Four Years Disappointing conclusion to Omega Protein’s strategic alternatives review » The Company never established a customary special Strategic Review Committee of independent members of the Board. » S

  29. Slide 29: Poor Corporate Governance Reflects Entrenched Board of Directors

    Slide 29: Poor Corporate Governance Reflects Entrenched Board of Directors

    29 Poor Corporate Governance Reflects Entrenched Board of Directors

  30. Slide 30: Poor Corporate Governance

    Slide 30: Poor Corporate Governance

    30 Poor Corporate Governance Omega Protein has a classified board. Omega Protein has plurality voting. » Omega Protein’s proposal on the Annual Meeting agenda to adopt majority voting was put in place in response to shareholder pressure. Board is authorized to increase or decrease the size of the bo

  31. Slide 31: Hostile Actions Impacting Shareholders

    Slide 31: Hostile Actions Impacting Shareholders

    31 Hostile Actions Impacting Shareholders Shareholder Unfriendly Bylaw Provisions Recently Adopted by the Board – Without Shareholder Approval. » In 2015, Omega Protein’s Board twice unilaterally adopted, without shareholder approval, amendments to its Amended and Restated Bylaws: » Pushing back the

  32. Slide 32: Board Has a History of Terrible Corporate Governance

    Slide 32: Board Has a History of Terrible Corporate Governance

    32 Omega Protein Board Has a History of Terrible Corporate Governance & Unresponsiveness to it Shareholders » For the last several years, 4 Omega Directors (at least half of the Omega Board) have served on the Board, despite having pre vio usly received a majority of withhold votes cast against thei

  33. Slide 33: Poor Compensation Practices and Poor Alignment with Shareholders

    Slide 33: Poor Compensation Practices and Poor Alignment with Shareholders

    33 Poor Compensation Practices and Poor Alignment with Shareholders » At least one executive has a change - in - control agreement with a single trigger provision. (John D. Held) » Excise tax gross - ups are provided for in at least one employment agreement. (John D. Held) » Outstanding equity award

  34. Slide 34: Omega Protein has No Skin in the Game

    Slide 34: Omega Protein has No Skin in the Game

    34 Omega Protein has No “Skin in the Game” and Is Not Aligned with Omega Shareholders » The entire OME Board owns only 243,964 shares or 0.01% of OME outstanding shares, and even those were primarily acquired thro ugh equity awards granted to them. (1) » With more than 40 years of experience on the

  35. Slide 35: Omega Protein Negotiated in Bad Faith

    Slide 35: Omega Protein Negotiated in Bad Faith

    35 Omega Protein Negotiated in Bad Faith » Throughout the months of March and April, 2016, Wynnefield negotiated in good faith with Omega Protein in order to arrive at a mutually agreeable resolution of this proxy contest. » Following Wynnefield’s settlement offer of April 8, 2016, Omega Protein rem

  36. Slide 36: Omega Protein's Proposal No. 4: Too Little, Too Late

    Slide 36: Omega Protein's Proposal No. 4: Too Little, Too Late

    36 Omega Protein’s Proposal No. 4 Too Little, Too Late » Omega’s Proposal No. 4 - implementing majority voting for director elections - is a sham to try to make Omega’s Bylaws appear to be shareholder friendly and try to score some governance points with proxy advisory firms. » However, the truth is

  37. Slide 37: Conclusion

    Slide 37: Conclusion

    37 Conclusion

  38. Slide 38: Wynnefield Asks For Your Support

    Slide 38: Wynnefield Asks For Your Support

    38 Wynnefield Asks For Your Support VOTE FOR Independent Board Nominee Michael N. Christodolou » FOR electing directors with superior experience and expertise » FOR improving capital allocation policy » FOR addressing corporate governance

  39. Slide 39: Appendix I: Unfriendly Bylaws

    Slide 39: Appendix I: Unfriendly Bylaws

    39 Unfriendly Bylaws Appendix I » Recent Amendments – Slides 40 - 42 . » Original Bylaws – Slide 43 .

  40. Slide 40: Anti-Shareholder Bylaws: Recent Amendments

    Slide 40: Anti-Shareholder Bylaws: Recent Amendments

    40 Anti - Shareholder Bylaws – Purposefully to Deter Suffrage Recent Amendments Section 1.2: Annual Meetings – Adopted 11/5/15. » Requirement for Omega Protein to hold its annual meeting no later than 210 days after end of the fiscal year was removed; the annual meeting now may be held at any time d

  41. Slide 41: Anti-Shareholder Bylaws: Recent Amendments

    Slide 41: Anti-Shareholder Bylaws: Recent Amendments

    41 Anti - Shareholder Bylaws – Purposefully to Deter Suffrage Recent Amendments Section 1.10: Further Amendment – Adopted 11/5/15. » Provision requires stockholders to provide further burdensome information with respect to bringing before a stockholder meeti ng; added the additional requirement that

  42. Slide 42: Anti-Shareholder Bylaws: Forum for Adjudication of Disputes

    Slide 42: Anti-Shareholder Bylaws: Forum for Adjudication of Disputes

    42 Anti - Shareholder Bylaws – Purposefully to Deter Suffrage Recent Amendments Article XI: Forum For Adjudication of Disputes – Adopted 11/5/15. » Shareholder unfriendly provision requiring that the District Courts of the State of Nevada located in Clark or Washoe countie s b e the sole and exclusi

  43. Slide 43: Anti-Shareholder Bylaws: Original Bylaws

    Slide 43: Anti-Shareholder Bylaws: Original Bylaws

    43 Anti - Shareholder Bylaws Original Bylaws Section 2.3: Classes of Directors and term of Office – Original Bylaws. » Section provides for a classified Board of Directors with three classes of directors. Section 2.4.1: Election of Directors – Original Bylaws. » Provision provides for plurality voti

  44. Slide 44: Appendix II: Dialogue Summary

    Slide 44: Appendix II: Dialogue Summary

    44 » Dialogue Summary » See Slides 45 - 47 Engagement Timeline Between Wynnefield and Omega Protein Appendix II

  45. Slide 45: Engagement Timeline Between Wynnefield and Omega Protein

    Slide 45: Engagement Timeline Between Wynnefield and Omega Protein

    45 Engagement Timeline Between Wynnefield and Omega Protein Dialogue Summary » June - July 2015 : Several conversations with Mr. Scholtes – the Company’s President and CEO – regarding its misallocation of capital into Human Nutrition at the expense of its core Animal Nutrition operations. Given the

  46. Slide 46: » March 1, 2016 : Wynnefield’s counsel responded to the Company’s counsel request seeking

    Slide 46: » March 1, 2016 : Wynnefield’s counsel responded to the Company’s counsel request seeking

    46 » March 1, 2016 : Wynnefield’s counsel responded to the Company’s counsel request seeking further information with respect to Wynnefield’s nominees as of February 23, 2016. Wynnefield filed an amendment to its Schedule 13D. » March 9, 2016 : The Company filed its Annual Report on Form 10 - K – wh

  47. Slide 47: Engagement Timeline Between Wynnefield and Omega Protein

    Slide 47: Engagement Timeline Between Wynnefield and Omega Protein

    47 Engagement Timeline Between Wynnefield and Omega Protein Dialogue Summary Note: All engagement timeline details are located in Wynnefield’s proxy on page 10 - 15. » April 19, 2016 : After not hearing from the Company’s counsel, Wynnefield’s counsel placed two calls to the Company’s counsel on Apr

  48. Slide 48: Omega Protein: A Case of Poor Board Quality, Capital Misallocation and Anti-Shareholder Corporate Governance

    Slide 48: Omega Protein: A Case of Poor Board Quality, Capital Misallocation and Anti-Shareholder Corporate Governance

    Omega Protein: A Case of Poor Board Quality, Capital Misallocation and Anti - Shareholder Corporate Governance © 2016 Wynnefield Capital, Inc. All rights reserved.

Source: SEC EDGAR · DFAN14A filed Jun 8, 2016

More decks from Omega Protein Corp